<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Blood</journal-id>
      <journal-id journal-id-type="iso-abbrev">Blood</journal-id>
      <journal-id journal-id-type="hwp">bloodjournal</journal-id>
      <journal-id journal-id-type="pmc">blood</journal-id>
      <journal-id journal-id-type="publisher-id">Blood</journal-id>
      <journal-title-group>
        <journal-title>Blood</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0006-4971</issn>
      <issn pub-type="epub">1528-0020</issn>
      <publisher>
        <publisher-name>American Society of Hematology</publisher-name>
        <publisher-loc>Washington, DC</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25733584</article-id>
      <article-id pub-id-type="pmc">4408290</article-id>
      <article-id pub-id-type="publisher-id">2014/583351</article-id>
      <article-id pub-id-type="doi">10.1182/blood-2014-06-583351</article-id>
      <article-categories>
        <subj-group subj-group-type="hwp-journal-coll">
          <subject>29</subject>
          <subject>8</subject>
          <subject>36</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Clinical Trials and Observations</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Telen</surname>
            <given-names>Marilyn J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wun</surname>
            <given-names>Ted</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McCavit</surname>
            <given-names>Timothy L.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Castro</surname>
            <given-names>Laura M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Krishnamurti</surname>
            <given-names>Lakshmanan</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lanzkron</surname>
            <given-names>Sophie</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hsu</surname>
            <given-names>Lewis L.</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>Wally R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rhee</surname>
            <given-names>Seungshin</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magnani</surname>
            <given-names>John L.</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thackray</surname>
            <given-names>Helen</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">10</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Medicine, Division of Hematology, Duke University, Durham, NC; </aff>
        <aff id="aff2"><label>2</label>Department of Internal Medicine, Division of Hematology/Oncology, University of California Davis Medical Center and VA Northern California Health Care System, Sacramento, CA; </aff>
        <aff id="aff3"><label>3</label>Department of Pediatric Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX; </aff>
        <aff id="aff4"><label>4</label>Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA; </aff>
        <aff id="aff5"><label>5</label>Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; </aff>
        <aff id="aff6"><label>6</label>Department of Medicine, Division of Hematology, Johns Hopkins School of Medicine, Baltimore, MD; </aff>
        <aff id="aff7"><label>7</label>Department of Pediatrics, University of Illinois, Chicago, IL; </aff>
        <aff id="aff8"><label>8</label>Division of General Internal Medicine, Virginia Commonwealth University, Richmond, VA; </aff>
        <aff id="aff9"><label>9</label>Rho, Inc., Chapel Hill, NC; and </aff>
        <aff id="aff10"><label>10</label>GlycoMimetics, Inc., Gaithersburg, MD</aff>
      </contrib-group>
      <pub-date pub-type="ppub">
        <day>23</day>
        <month>4</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epreprint">
        <day>02</day>
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>23</day>
        <month>4</month>
        <year>2015</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <volume>125</volume>
      <issue>17</issue>
      <fpage>2656</fpage>
      <lpage>2664</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>2</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="2656.pdf"/>
      <abstract abstract-type="executive-summary">
        <title>Key Points</title>
        <p>
          <list list-type="bullet">
            <list-item>
              <p>GMI-1070 led to statistically insignificant but large reductions in time to resolution of VOC and a significant reduction in opioid use.</p>
            </list-item>
            <list-item>
              <p>These results support a role for selectins in VOC and progression to a phase 3 study of GMI-1070 for SCD patients with vaso-occlusion.</p>
            </list-item>
          </list>
        </p>
      </abstract>
      <abstract>
        <p>Treatment of vaso-occlusive crises (VOC) or events in sickle cell disease (SCD) remains limited to symptom relief with opioids. Animal models support the effectiveness of the pan-selectin inhibitor GMI-1070 in reducing selectin-mediated cell adhesion and abrogating VOC. We studied GMI-1070 in a prospective multicenter, randomized, placebo-controlled, double-blind, phase 2 study of 76 SCD patients with VOC. Study drug (GMI-1070 or placebo) was given every 12 hours for up to 15 doses. Other treatment was per institutional standard of care. All subjects reached the composite primary end point of resolution of VOC. Although time to reach the composite primary end point was not statistically different between the groups, clinically meaningful reductions in mean and median times to VOC resolution of 41 and 63 hours (28% and 48%, <italic>P =</italic> .19 for both) were observed in the active treatment group vs the placebo group. As a secondary end point, GMI-1070 appeared safe in acute vaso-occlusion, and adverse events were not different in the two arms. Also in secondary analyses, mean cumulative IV opioid analgesic use was reduced by 83% with GMI-1070 vs placebo (<italic>P =</italic> .010). These results support a phase 3 study of GMI-1070 (now rivipansel) for SCD VOC. This trial was registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> as #NCT01119833.</p>
      </abstract>
      <counts>
        <page-count count="9"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>access</meta-name>
          <meta-value>free</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
</article>

